Basic Information
SPRYCEL TABLETS 50MG
TABLET, FILM COATED
Regulatory Information
SIN13354P
September 14, 2007
Prescription Only
Therapeutic
ORAL
August 10, 2023
June 3, 2025
Company Information
BRISTOL-MYERS SQUIBB (SINGAPORE) PTE. LTD.
BRISTOL-MYERS SQUIBB (SINGAPORE) PTE. LTD.
Active Ingredients
Strength: 50mg per tab
Detailed Information
Contraindications
**4 CONTRAINDICATIONS** Hypersensitivity to the active substance or to any of the excipients.
Indication Information
**1 INDICATIONS AND USAGE** SPRYCEL® (dasatinib) is indicated for the treatment of adult patients with - newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase. - chronic, accelerated, or myeloid or lymphoid blast phase CML with resistance or intolerance to prior therapy including imatinib. - Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy. SPRYCEL® (dasatinib) is indicated for the treatment of pediatric patients with - newly diagnosed Ph+ CML in chronic phase or Ph+ CML-CP resistant or intolerant to prior therapy including imatinib. - newly diagnosed Ph+ ALL in combination with chemotherapy.